PARP14 is a novel target in STAT6 mutant follicular lymphoma
© 2022. The Author(s)..
The variable clinical course of follicular lymphoma (FL) is determined by the molecular heterogeneity of tumor cells and complex interactions within the tumor microenvironment (TME). IL-4 producing follicular helper T cells (TFH) are critical components of the FL TME. Binding of IL-4 to IL-4R on FL cells activates JAK/STAT signaling. We identified STAT6 mutations (STAT6MUT) in 13% of FL (N = 33/258), all clustered within the DNA binding domain. Gene expression data and immunohistochemistry showed upregulation of IL-4/STAT6 target genes in STAT6MUT FL, including CCL17, CCL22, and FCER2 (CD23). Functionally, STAT6MUT was gain-of-function by serial replating phenotype in pre-B CFU assays. Expression of STAT6MUT enhanced IL-4 induced FCER2/CD23, CCL17 and CCL22 expression and was associated with nuclear accumulation of pSTAT6. RNA sequencing identified PARP14 -a transcriptional switch and co-activator of STAT6- among the top differentially upregulated genes in IL-4 stimulated STAT6MUT lymphoma cells and in STAT6MUT primary FL cells. Quantitative chromatin immunoprecipitation (qChIP) demonstrated binding of STAT6MUT but not STAT6WT to the PARP14 promotor. Reporter assays showed increased IL-4 induced transactivation activity of STAT6MUT at the PARP14 promotor, suggesting a self-reinforcing regulatory circuit. Knock-down of PARP14 or PARP-inhibition abrogated the STAT6MUT gain-of-function phenotype. Thus, our results identify PARP14 as a novel therapeutic target in STAT6MUT FL.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:36 |
|---|---|
| Enthalten in: |
Leukemia - 36(2022), 9 vom: 31. Sept., Seite 2281-2292 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
207137-56-2 |
|---|
| Anmerkungen: |
Date Completed 30.08.2022 Date Revised 10.10.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41375-022-01641-x |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM343713403 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM343713403 | ||
| 003 | DE-627 | ||
| 005 | 20231226021106.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41375-022-01641-x |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1145.xml |
| 035 | |a (DE-627)NLM343713403 | ||
| 035 | |a (NLM)35851155 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mentz, Michael |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a PARP14 is a novel target in STAT6 mutant follicular lymphoma |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 30.08.2022 | ||
| 500 | |a Date Revised 10.10.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022. The Author(s). | ||
| 520 | |a The variable clinical course of follicular lymphoma (FL) is determined by the molecular heterogeneity of tumor cells and complex interactions within the tumor microenvironment (TME). IL-4 producing follicular helper T cells (TFH) are critical components of the FL TME. Binding of IL-4 to IL-4R on FL cells activates JAK/STAT signaling. We identified STAT6 mutations (STAT6MUT) in 13% of FL (N = 33/258), all clustered within the DNA binding domain. Gene expression data and immunohistochemistry showed upregulation of IL-4/STAT6 target genes in STAT6MUT FL, including CCL17, CCL22, and FCER2 (CD23). Functionally, STAT6MUT was gain-of-function by serial replating phenotype in pre-B CFU assays. Expression of STAT6MUT enhanced IL-4 induced FCER2/CD23, CCL17 and CCL22 expression and was associated with nuclear accumulation of pSTAT6. RNA sequencing identified PARP14 -a transcriptional switch and co-activator of STAT6- among the top differentially upregulated genes in IL-4 stimulated STAT6MUT lymphoma cells and in STAT6MUT primary FL cells. Quantitative chromatin immunoprecipitation (qChIP) demonstrated binding of STAT6MUT but not STAT6WT to the PARP14 promotor. Reporter assays showed increased IL-4 induced transactivation activity of STAT6MUT at the PARP14 promotor, suggesting a self-reinforcing regulatory circuit. Knock-down of PARP14 or PARP-inhibition abrogated the STAT6MUT gain-of-function phenotype. Thus, our results identify PARP14 as a novel therapeutic target in STAT6MUT FL | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a STAT6 Transcription Factor |2 NLM | |
| 650 | 7 | |a STAT6 protein, human |2 NLM | |
| 650 | 7 | |a Interleukin-4 |2 NLM | |
| 650 | 7 | |a 207137-56-2 |2 NLM | |
| 650 | 7 | |a PARP14 protein, human |2 NLM | |
| 650 | 7 | |a EC 2.4.2.30 |2 NLM | |
| 650 | 7 | |a Poly(ADP-ribose) Polymerases |2 NLM | |
| 650 | 7 | |a EC 2.4.2.30 |2 NLM | |
| 700 | 1 | |a Keay, William |e verfasserin |4 aut | |
| 700 | 1 | |a Strobl, Carolin Dorothea |e verfasserin |4 aut | |
| 700 | 1 | |a Antoniolli, Martina |e verfasserin |4 aut | |
| 700 | 1 | |a Adolph, Louisa |e verfasserin |4 aut | |
| 700 | 1 | |a Heide, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Lechner, Axel |e verfasserin |4 aut | |
| 700 | 1 | |a Haebe, Sarah |e verfasserin |4 aut | |
| 700 | 1 | |a Osterode, Elisa |e verfasserin |4 aut | |
| 700 | 1 | |a Kridel, Robert |e verfasserin |4 aut | |
| 700 | 1 | |a Ziegenhain, Christoph |e verfasserin |4 aut | |
| 700 | 1 | |a Wange, Lucas Esteban |e verfasserin |4 aut | |
| 700 | 1 | |a Hildebrand, Johannes Adrian |e verfasserin |4 aut | |
| 700 | 1 | |a Shree, Tanaya |e verfasserin |4 aut | |
| 700 | 1 | |a Silkenstedt, Elisabeth |e verfasserin |4 aut | |
| 700 | 1 | |a Staiger, Annette M |e verfasserin |4 aut | |
| 700 | 1 | |a Ott, German |e verfasserin |4 aut | |
| 700 | 1 | |a Horn, Heike |e verfasserin |4 aut | |
| 700 | 1 | |a Szczepanowski, Monika |e verfasserin |4 aut | |
| 700 | 1 | |a Richter, Julia |e verfasserin |4 aut | |
| 700 | 1 | |a Levy, Ronald |e verfasserin |4 aut | |
| 700 | 1 | |a Rosenwald, Andreas |e verfasserin |4 aut | |
| 700 | 1 | |a Enard, Wolfgang |e verfasserin |4 aut | |
| 700 | 1 | |a Zimber-Strobl, Ursula |e verfasserin |4 aut | |
| 700 | 1 | |a von Bergwelt-Baildon, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Hiddemann, Wolfgang |e verfasserin |4 aut | |
| 700 | 1 | |a Klapper, Wolfram |e verfasserin |4 aut | |
| 700 | 1 | |a Schmidt-Supprian, Marc |e verfasserin |4 aut | |
| 700 | 1 | |a Rudelius, Martina |e verfasserin |4 aut | |
| 700 | 1 | |a Bararia, Deepak |e verfasserin |4 aut | |
| 700 | 1 | |a Passerini, Verena |e verfasserin |4 aut | |
| 700 | 1 | |a Weigert, Oliver |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Leukemia |d 1989 |g 36(2022), 9 vom: 31. Sept., Seite 2281-2292 |w (DE-627)NLM012593788 |x 1476-5551 |7 nnns |
| 773 | 1 | 8 | |g volume:36 |g year:2022 |g number:9 |g day:31 |g month:09 |g pages:2281-2292 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41375-022-01641-x |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 36 |j 2022 |e 9 |b 31 |c 09 |h 2281-2292 | ||